Bio-Techne Corporation Bio-Techne Corporation

Bio-Techne Corporation

TECH

Rang în acțiuni #1867
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures,... Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Preț acțiune
$72.55
Ultima sincronizare: 2026-10-16
Capitalizare de piață
$11.38B
Schimbare (1 zi)
0.03%
Schimbare (1 an)
17.27%
Țară
US
Tranzacționează Bio-Techne Corporation (TECH)

Categorie

Healthcare
Raport P/E pentru Bio-Techne Corporation (TECH)
Raport P/E la data de October 2026 TTM: 61.97
Conform celor mai recente rapoarte financiare și prețului acțiunilor Bio-Techne Corporation, raportul P/E actual (TTM) este 61.97. La sfârșitul anului 2024, compania avea un P/E de 67.18.
Istoricul raportului P/E pentru Bio-Techne Corporation din 2000 până în 2026
Raportul P/E la sfârșitul fiecărui an
An Raport P/E Schimbă
2026 (TTM) 61.97 -43.88%
2025 110.41 64.35%
2024 67.18 49.36%
2023 44.98 -9.99%
2022 49.97 -59.78%
2021 124.26 182.43%
2020 44.00 -46.54%
2019 82.30 86.05%
2018 44.24 -22.03%
2017 56.74 41.34%
2016 40.14 18.38%
2015 33.91 10.18%
2014 30.78 34.96%
2013 22.80 -6.55%
2012 24.40 -11.39%
2011 27.54 41.26%
2010 19.49 -14.94%
2009 22.92 -21.66%
2008 29.25 10.46%
2007 26.48 -2.30%
2006 27.11 -3.27%
2005 28.02 -16.81%
2004 33.69 21.76%
2003 27.67 -35.05%
2002 42.59 7.61%
2001 39.58 -60.15%
2000 99.34 0.00%
Raportul P/E pentru companii similare sau concurenți
Companie P/E Ratio Diferență P/E Ratio Țara
28.78 -53.55%
US
-28.36 -145.76%
US
-24.57 -139.65%
AU
- -
CH
30.33 -51.05%
NL
Cum interpretezi un P/E ratio?

Raportul Preț/Câștig (P/E Ratio) măsoară relația dintre prețul acțiunii unei companii și câștigul pe acțiune.
Un P/E scăzut dar pozitiv indică o companie cu profituri mari în raport cu evaluarea actuală și ar putea fi subevaluată. Un P/E negativ mare (aproape de 0) indică pierderi majore.

Companiile cu un P/E peste 30 sau negativ sunt considerate în general „acțiuni de creștere”, adică investitorii se așteaptă la creștere sau profitabilitate viitoare.

Companiile cu un P/E pozitiv sub 10 sunt considerate „acțiuni de valoare”, adică sunt deja profitabile, dar cu șanse mici de creștere suplimentară.